Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204041) titled 'Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Condition:
Langerhans Cell Histiocytosis (LCH)
Intervention:
Drug: Selinexor
Drug: Thalidomide (100mg)
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 1, 2025
Target Sample Size: 40
Countries ...